Heidelberg Pharma AG (0QW5.L)

2,9900 -0,1100 (-3,55%) Alla chiusura: 11:09AM BST

Heidelberg Pharma AG

Gregor-Mendel-Strasse 22
Ladenburg 68526
Germany
49 6203 1009 0
https://heidelberg-pharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 95

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Prof. Andreas Pahl	CEO & Spokesman of the Executive Board	328,28k	N/D	N/D
Mr. Walter Miller	Chief Financial Officer	N/D	N/D	N/D
Dr. Jorg Kemkowski	Chief Operating Officer	N/D	N/D	N/D
Sylvia Wimmer	Director Corporate Communication	N/D	N/D	N/D
Dr. Andras Strassz	Chief Medical Officer	N/D	N/D	N/D
Dr. George Octavian Badescu	Chief Business Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; and triple-negative breast cancer. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

Governance aziendale

L'ISS Governance QualityScore di Heidelberg Pharma AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.